Rituximab in lymphomatoid granulomatosis.

Abstract

BACKGROUND:

Lymphomatoid granulomatosis (LG) is an Epstein-Barr virus-associated, multisystemic disease that combines a granulomatous inflammatory process with lymphoproliferative potential. It is a rare disorder with a variable clinical presentation ranging from an indolent process to an aggressive B-cell lymphoma. Outcome is unpredictable, and a standard treatment has not yet been established. Cases treated with rituximab, an anti-CD20 monoclonal antibody, have been reported with variable results.

OBSERVATION:

We report on 2 children with LG treated with rituximab and review the literature. The first patient had good response but the second did not.

CONCLUSIONS:

Rituximab is a treatment option for LG.

• Authors: Carmen Hernández-Marqués, Alvaro Lassaletta, Antonio Torrelo, Miguel Ángel López-Pino, Javier Álvarez-Coca, Inmaculada De Prada, Ángela Hernández-Martín, Luis Madero
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 36 Issue 2 Pg. e69-74 (Mar 2014) ISSN: 1536-3678 [Electronic] United States
• PMID: 23337550 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Child, Preschool
• Humans
• Lymphomatoid Granulomatosis (drug therapy)
• Male
• Rituximab